Information
LOS ANGELES, Jan. 19, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. ("Vistagen " or "the Company") (NASDAQ: VTGN ) for violations
Original sourceAI Summary
Vistagen Therapeutics is being sued for misleading investors about its fasedienol trial results, with the class action period covering April 2024 to December 2025. This legal action could have significant financial implications for the company, particularly if the claims are substantiated.
Sentiment Rationale
Similar past instances show that lawsuits often depress stock prices due to uncertainty about legal outcomes and potential financial repercussions.
Trading Thesis
Given the legal challenges, VTGN shares may face significant downward pressure in the short term.
Market-Moving
- Continued declining share price is likely as investor confidence wanes due to lawsuit.
- Potential financial liabilities stemming from the class action could impact future operations.
- Loss of credibility could deter new investors following negative media coverage.
- Upcoming court deadlines may trigger increased volatility in share price.
Key Facts
- Vistagen is facing a class action lawsuit over misleading statements.
- Lawsuit alleges false information regarding fasedienol trial results.
- Class period runs from April 2024 to December 2025.
- Investors may seek lead plaintiff appointments for legal recovery.
- Deadline for participation in the class action is March 16, 2026.
Companies Mentioned
- Vistagen Therapeutics, Inc. (VTGN): Facing substantial legal risks that may adversely affect stock price.
Corporate Developments
The legal developments surrounding Vistagen fit within the 'Corporate Developments' category, as they directly pertain to the company's obligations to its investors regarding truthful disclosures and the resulting implications on its share price.
LOS ANGELES, Jan. 19, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. ("Vistagen " or "the Company") (NASDAQ: VTGN ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of VTGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: April 1, 2024 to December 16, 2025
DEADLINE: March 16, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Vistagen misled investors about the results of its PALISADE-2 trial of fasedienol. The Company created the false impression that its drug candidate would enjoy a successful Phase 3 trial. Based on these facts, Vistagen's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate .
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: David@djslawllp.com
View original content:https://www.prnewswire.com/news-releases/vistagen-therapeutics-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--vtgn-302664166.html
SOURCE DJS Law Group LLP